Cue Biopharma reports Q4 net income of $1.6M on $21.9M collab revenue from ImmunoScape; cash $27.1M

Cue Biopharma, Inc.

Net income $1.585M ($0.01 EPS) in Q4 2025 vs net loss $9.496M in Q4 2024; full-year net loss $26.6M vs $40.7M.
Collaboration revenue $21.9M in Q4 vs $1.6M; primarily from $9.5M upfront from ImmunoScape deal, with $5M due Nov 2026.
R&D expenses $16.5M (up from $7.2M) on CUE-401 mfg and ImmunoScape-related costs; G&A $3.5M (down from $4.0M).
Appointed Lucinda Warren CFO; raised $10.2M net in public offering; cash $27.1M at Dec 31, 2025.
Advanced CUE-401 autoimmune drug toward IND; reported preclinical safety data; plans Virtual R&D Day.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cue Biopharma, Inc. reported the year ended December 31, 2025 results: revenue $27.5 million.

Period: the year ended December 31, 2025
Revenue: $27.5 million
Result: reported results

Exact text from the filing

The Company reported collaboration revenue of $27.5 million and $9.3 million for the years ended December 31, 2025 and 2024, respectively.

View on SEC.gov

Earnings Releases SEC 8-K Item 2.02 confidence 1.0

Cue Biopharma, Inc. reported the three months ended December 31, 2025 results: revenue $21.9 million.

Period: the three months ended December 31, 2025
Revenue: $21.9 million
Result: reported results

Exact text from the filing

The Company reported collaboration revenue of $21.9 million and $1.6 million for the three months ended December 31, 2025 and 2024, respectively.

View on SEC.gov

51 earnings releases filed in the last 30 days. Browse all earnings releases →

Cue Biopharma, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-108292

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.